Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Common Equity: 2013-2025

Historic Common Equity for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $258.2 million.

  • Ocular Therapeutix's Common Equity fell 26.64% to $258.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.2 million, marking a year-over-year decrease of 26.64%. This contributed to the annual value of $315.3 million for FY2024, which is 246.03% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Common Equity of $258.2 million as of Q3 2025, which was down 15.59% from $305.9 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Common Equity peaked at $408.0 million during Q1 2024, and registered a low of $3.1 million during Q2 2023.
  • In the last 3 years, Ocular Therapeutix's Common Equity had a median value of $265.9 million in 2025 and averaged $217.7 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Common Equity slumped by 95.31% in 2023, and later skyrocketed by 12,135.02% in 2024.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Common Equity stood at $88.0 million in 2021, then plummeted by 59.80% to $35.4 million in 2022, then surged by 157.59% to $91.1 million in 2023, then skyrocketed by 246.03% to $315.3 million in 2024, then fell by 26.64% to $258.2 million in 2025.
  • Its Common Equity was $258.2 million in Q3 2025, compared to $305.9 million in Q2 2025 and $265.9 million in Q1 2025.